Liesbeth Ruijgrok is a Hospital Pharmacist and Assistant Professor that is highly motivated to improve the availability of suitable medicines for neglected patient groups. Her PhD project at Erasmus MC was about the use of inhaled amphotericin B formulations for the prevention and treatment of invasive aspergillosis. This work consisted of formulation and development of inhalable (liposomal) drugs, pre-clinical experiments and clinical trials. After her PhD and internship in Erasmus MC, she worked as a hospital pharmacist in Amsterdam UMC and Maasstad Hospital Rotterdam. Clinical pharmacy (especially oncology and pulmonology), drug manufacturing and drug development were the focus points of her work between 2004 and 2018. In 2018, she seized the opportunity to return to Erasmus MC. The innovative and research-oriented atmosphere in Erasmus MC contributed to the decision to make this switch in her career. She is Principal Investigator in the Research Pillar “Drug Innovation and Drug Development” of the Hospital Pharmacy. She is an enthusiastic collaborator in several scientific projects that concern in-academia development of drugs, varying from small molecules to cell therapy products (ATMP) and cancer vaccines. In 2019, the possibility of 3D-printing of drugs has aroused her interest. An intensive and fruitful collaboration with TNO started. The 3D-printing technology can substantially enlarge personalized treatment options since it allows for flexible and tuneable drug compounding. She is affiliated to a growing Dutch and European consortium in this field and currently supervises 4 PhD students on the topic of 3D pharmaprinting. Her ultimate goal: to bring this exciting new technology as soon as possible to the benefit of patients!